ALB and type 2 diabetes mellitus: Mean corpus recovery (MCR) was significantly lower with semaglutide than with placebo (9%; p = 0.035), but not with empagliflozin. Empagliflozin had no effect on the urinary albumin-to-creatinine ratio (UNACR), but semaglutide reduced it by 35% (p = 0.003). The ePV fell in the combination group. There was no discernible difference in MCR between patients with and without type 2 diabetes.